Ocugen (OCGN) Research & Development (2014 - 2026)
Ocugen's (OCGN) quarterly Research & Development came in at $11.3 million in Q1 2026, up 18.11% YoY from $9.5 million in Q1 2025, and up 5.49% on a QoQ basis from $10.7 million in Q4 2025.
Ocugen (OCGN) Research & Development (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Research & Development data on file, last reported at $11.3 million in Q1 2026.
- Quarterly Research & Development rose 18.11% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.5 million (up 19.08% YoY) and the FY2025 annual result came in at $39.8 million, up 23.73% from the prior year.
- Research & Development advanced to $11.3 million in Q1 2026, from $10.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $17.9 million in Q3 2022 to a low of $6.8 million in Q1 2024.
- A 5-year average of $10.5 million and a median of $9.5 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 227.05% — and 2023, when it slumped 60.71%.
- Tracing OCGN's Research & Development over 5 years: stood at $17.2 million in 2022, then slumped by 54.84% to $7.8 million in 2023, then grew by 6.57% to $8.3 million in 2024, then advanced by 28.7% to $10.7 million in 2025, then rose by 5.49% to $11.3 million in 2026.
- The last three Research & Development figures came in at $11.3 million (Q1 2026), $10.7 million (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 10.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.69 Mn |
| Mar 31, 2026 | 11.26 Mn |
| Dec 31, 2025 | 10.67 Mn |
| Sep 30, 2025 | 11.15 Mn |
| Jun 30, 2025 | 8.40 Mn |
| Mar 31, 2025 | 9.53 Mn |
| Dec 31, 2024 | 8.29 Mn |
| Sep 30, 2024 | 8.11 Mn |
| Jun 30, 2024 | 8.90 Mn |
| Mar 31, 2024 | 6.83 Mn |
| Dec 31, 2023 | 7.78 Mn |
| Sep 30, 2023 | 7.05 Mn |
| Jun 30, 2023 | 14.57 Mn |
| Mar 31, 2023 | 10.17 Mn |
| Dec 31, 2022 | 17.23 Mn |
| Sep 30, 2022 | 17.94 Mn |
| Jun 30, 2022 | 11.60 Mn |
| Mar 31, 2022 | 9.39 Mn |
| Dec 31, 2021 | 7.10 Mn |
| Sep 30, 2021 | 6.28 Mn |